Quarter
Charts

BALCHEM CORPORATION

BCPC

CIK 0000009326 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$264M
↑+9.8% +$24Mvs FY2024 (Q4)
Operating Income
$52M
↑+10.2% +$5Mvs FY2024 (Q4)
Net Income
$39M
↑+16.8% +$6Mvs FY2024 (Q4)
Gross Profit
$94M
↑+8.8% +$8Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Average
60/100
  • Profitability
    43ROIC 13.5% (10% = solid, 20%+ = moat)
  • Liquidity
    79Current Ratio 2.07 (above 1.5 = solid)
  • Leverage
    89D/E 0.23 (under 0.5 = conservative)
  • Efficiency
    34Asset Turnover 0.64x (1.0+ = capital-efficient)
  • Growth
    49Revenue YoY +9.8% (10% = solid, 25%+ = elite)
  • Margin Trend
    67Op Margin 19.8% · trend +1.0pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

DCF intrinsic value

DCF intrinsic value

two-stage Gordon model

Project BCPC's free cash flow forward, discount back at your hurdle rate, divide by diluted shares. Edit the assumptions to see how sensitive the intrinsic value is.

25%

Trailing 3-yr CAGR was 34.3%

10%

10% is a common all-equity benchmark for US large-caps

2.5%

Should be ≤ long-run GDP growth (~2.5% nominal)

5

5-year explicit projection + perpetuity terminal

Intrinsic value per share
$221.54
Total enterprise IV
$7.22B
Diluted shares
0.03B
Terminal PV
$5.61B (78% of total)
Year-5 FCF
$661M
YearProjected FCFDiscounted PV
+1$271M$246M
+2$338M$280M
+3$423M$318M
+4$529M$361M
+5$661M$410M
Terminal$9.03B$5.61B

DCF outputs are HIGHLY sensitive to growth + WACC assumptions. A 1pp WACC change can shift IV by 20%+. Use this as a sanity-check vs market price, not a target — and always cross-check the underlying FCF source (EDGAR cashflow statement, latest annual). Margin of safety convention: 30-50% discount to IV before buying.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
—
investment in PP&E
Dividends paid (TTM)
$28M
cash returned to holders
Stock buybacks (TTM)
$108M
share count reduction
Stock-based comp (TTM)
$18M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$1.69B
everything owned
Total liabilities
$429M
everything owed
Stockholders' equity
$1.26B
shareholder claim
Net debt
$81M
LT debt minus cash

Recent performance · 64 quarters

Revenue↑+9.8% +$24M
$264M
Net Income↑+16.8% +$6M
$39M
Free Cash Flow↑+28.6% +$15M
$67M
Operating Margin↑+0.1pts
19.8%

Drill down

BCPC Sankey

See BALCHEM CORPORATION's revenue flow into every line item of the income statement and balance sheet — every dollar accounted for, with prior-period comparison.

Open Sankey

BCPC Charts

64 quarters of historical line items — Income, Cash Flow, Balance Sheet, plus margins. Click any chart for the trend dialog.

Open Charts

BCPC Key Metrics

EPS, BVPS, FCF/Share, ROE, ROA, ROIC, D/E, Current Ratio, Quick Ratio, Asset Turnover — 10 CFA-grade fundamentals derived from EDGAR data.

Open Key Metrics